Expert Interview
A discussion of the NSCLC Exon 20 Insertion Landscape, with a focus on sunvozertinib from Dizal and potential readthrough to zipalertinib from Cullinan Oncology (CGEM)
Ticker(s): CGEM, DizalInstitution: University of Colorado
- Chair in Cancer Research, Distinguished Professor, Medicine-Medical Oncology, & Founding Director of the University of Colorado Cancer Center.
- Past president of the International Association for the Study of Lung Cancer (IASLC) and the American Society of Clinical Oncology (ASCO); served as chairman of the FDA Oncology Drug Advisory Committee.
- Currently managing 4 patients with mesothelioma.
- Research focuses on novel molecular therapies and immunotherapies for lung cancer and other thoracic cancers.
How are you currently treating patients with NSCLC EGFR Exon 20 Ins?
Added By: wilson_adminWhat are your impressions of sunvozertib?
What are your impressions of zipalertinib?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
